The Experts below are selected from a list of 1769004 Experts worldwide ranked by ideXlab platform

Gunter Bernhardt - One of the best experts on this subject based on the ideXlab platform.

  • cd96 targeted antibodies need not block cd96 CD155 interactions to promote nk cell anti metastatic activity
    OncoImmunology, 2018
    Co-Authors: Amelia Roman Aguilera, Gunter Bernhardt, Kimberley Stannard, Kazuyoshi Takeda, Viviana P Lutzky, Deepak Mittal, Michele W L Teng, William C Dougall, Mark J Smyth
    Abstract:

    CD96 is a transmembrane glycoprotein Ig superfamily receptor, expressed on various T cell subsets and NK cells, that interacts with nectin and nectin-like proteins, including CD155/polio virus receptor (PVR). Here, we have compared three rat anti-mouse CD96 mAbs, including two that block CD96-CD155 (3.3 and 6A6) and one that does not block CD96-CD155 (8B10). Using flow cytometry, we demonstrated that both mAbs 3.3 and 6A6 bind to the first Ig domain of mouse CD96 and compete with CD155 binding, while mAb 8B10 binds to the second Ig domain and does not block CD155. While Fc isotype was irrelevant concerning the anti-metastatic activity of 3.3 mAb, in four different experimental metastases models and one spontaneous metastasis model, the relative order of anti-metastatic potency was 6A6 > 3.3 > 8B10. The metastatic burden control of all of the anti-CD96 clones was highly dependent on NK cells and IFN-γ. Consistent with its inability to block CD96-CD155 interactions, 8B10 retained anti-metastatic activity in CD155-deficient mice, whereas 3.3 and 6A6 lost potency in CD155-deficient mice. Furthermore, 8B10 retained most of its anti-metastatic activity in IL-12p35-deficient mice whereas the activity of 3.3 and 6A6 were partially lost. All three mAbs were inactive in CD226-deficient mice. Altogether, these data demonstrate anti-CD96 need not block CD96-CD155 interactions (ie. immune checkpoint blockade) to promote NK cell anti-metastatic activity.

  • CD155 cd226 interaction impacts on the generation of innate cd8 thymocytes by regulating inkt cell differentiation
    European Journal of Immunology, 2016
    Co-Authors: Hristo Georgiev, Akira Shibuya, Inga Ravens, Reinhold Forster, Gunter Bernhardt
    Abstract:

    The cell surface receptor CD155 influences a variety of immune processes by binding to its ligands CD226, CD96, or TIGIT. Here, we report that the interaction of CD155 with CD226 in the thymus of BALB/c mice has a dual function. It directly influences the dwell time of memory-like CD8(+) T cells, while it is indirectly involved in generating these cells. It was shown earlier that a massive emergence of memory-like CD8 T cells in thymus crucially depends on abundant IL-4, secreted in steady state by iNKT2 (where iNKT is invariant NKT) cells, a subclass of iNKT cells. Here, we show that absence of either CD155 or CD226 in BALB/c mice causes a profound shift in the iNKT subtype composition in thymus, expanding the frequency and numbers of iNKT1 cells at the expense of iNKT2 cells, as well as iNKT17 cells. This shift results in a drop of available IL-4 and creates a scenario similar to that observed in C57BL/6 mice, where iNKT1 cells predominate and iNKT2 cells are much less frequent when compared with BALB/c mice. Yet also in C57BL/6 mice, lack of CD155 or CD226 provokes a further decline in iNKT2 cells, suggesting that the observed effects are not restricted to a particular inbred strain.

  • CD155 pvr necl5 mediates a costimulatory signal in cd4 t cells and regulates allergic inflammation
    Journal of Immunology, 2015
    Co-Authors: Yumi Yamashitakanemaru, Akira Shibuya, Gunter Bernhardt, Yuichi Takahashi, Yinan Wang, Satoko Taharahanaoka, Shinichiro Honda, Kazuko Shibuya
    Abstract:

    Although Th1 and Th2 cells are known to be involved in allergic inflammatory diseases, the molecular mechanisms underlying their differentiation are incompletely understood. In this study, we identified CD155 as a costimulatory molecule on CD4(+) T cells. Importantly, CD155-mediated signaling induced Th1 development in both humans and mice, as evidenced by production of IFN-γ and upregulation of Tbx21 transcription; these effects were independent of IL-12 but dependent on NF-κB-induced autocrine IFN-γ that triggered positive feedback via STAT1 activation. Mice genetically deficient in CD155 or treated with anti-CD155 Ab exhibited attenuated Th1-type contact hypersensitivity. Thus, CD155 plays an important regulatory role in helper T cell differentiation and allergic diseases.

  • increased cd112 expression in methylcholanthrene induced tumors in CD155 deficient mice
    PLOS ONE, 2014
    Co-Authors: Yoko Nagumo, Akiko Iguchimanaka, Yumi Yamashitakanemaru, Akira Shibuya, Gunter Bernhardt, Fumie Abe, Kazuko Shibuya
    Abstract:

    Tumor recognition by immune effector cells is mediated by antigen receptors and a variety of adhesion and costimulatory molecules. The evidence accumulated since the identification of CD155 and CD112 as ligands for DNAM-1 in humans and mice has suggested that the interactions between DNAM-1 and its ligands play an important role in T cell- and natural killer (NK) cell-mediated recognition and lysis of tumor cells. We have previously demonstrated that methylcholanthrane (MCA) accelerates tumor development in DNAM-1-deficient mice, and the CD155 level on MCA-induced tumors is significantly higher in DNAM-1-deficient mice than in wild-type (WT) mice. By contrast, Cd112 expression on the tumors is similar in WT and DNAM-1-deficient mice, suggesting that CD155 plays a major role as a DNAM-1 ligand in activation of T cells and NK cells for tumor immune surveillance. To address this hypothesis, we examined MCA-induced tumor development in CD155-deficient mice. Unexpectedly, we observed no significant difference in tumor development between WT and CD155-deficient mice. Instead, we found that Cd112 expression was significantly higher in the MCA-induced tumors of CD155-deficient mice than in those of WT mice. We also observed higher expression of DNAM-1 and lower expression of an inhibitory receptor, TIGIT, on CD8+ T cells in CD155-deficient mice. These results suggest that modulation of the expression of receptors and CD112 compensates for CD155 deficiency in immune surveillance against MCA-induced tumors.

  • poliomyelitis in transgenic mice expressing CD155 under the control of the tage4 promoter after oral and parenteral poliovirus inoculation
    Journal of General Virology, 2014
    Co-Authors: Shaukat Khan, Gunter Bernhardt, Hidemi Toyoda, Akiko Iwasaki, Melissa M Linehan, Akio Nomoto, Jeronimo Cello, Eckard Wimmer
    Abstract:

    An important step in poliovirus (PV) infection by the oral route in humans is replication of the virus in lymphatic tissues of the gastrointestinal (GI) tract, thought to be mainly in the Peyer’s patches of the small intestine. No immunocompetent transgenic (tg) mice that express human PV receptor (CD155) under the control of different promoters can be infected orally. The mouse orthologue of human CD155 is Tage4, a protein expressed at the surface of enterocytes and in the Peyer’s patches. We describe here the generation of a tg mouse model in which the Tage4 promoter was used to drive expression of the human PV receptor-coding region (Tage4-CD155tg mice). In this model, CD155 expression was observed by immunostaining in different regions in the Peyer’s patches but not in their germinal centres. Although a similar pattern of staining was observed between 3- and 6-week-old Tage4-CD155tg mice, poliomyelitis was only seen in the younger mice after PV infection by the oral route. When compared with TgPVR21 mice that expressed CD155 driven by its human promoter, 3-week-old Tage4-CD155tg mice were more susceptible to gut infection and paralysis following feeding with PV. Also, Tage4-CD155tg mice exhibited higher susceptibility to poliomyelitis after parenteral inoculation of PV. Remarkably, the LD50 after intracerebral inoculation of PV was similar in both CD155 tg mouse strains. The CD155 tg mouse model reported here, although moderately susceptible to oral infection, may be suitable to study mechanisms of PV replication in the gastrointestinal tract and to dissect important aspects of PV neuroinvasiveness.

Eckard Wimmer - One of the best experts on this subject based on the ideXlab platform.

  • poliomyelitis in transgenic mice expressing CD155 under the control of the tage4 promoter after oral and parenteral poliovirus inoculation
    Journal of General Virology, 2014
    Co-Authors: Shaukat Khan, Gunter Bernhardt, Hidemi Toyoda, Akiko Iwasaki, Melissa M Linehan, Akio Nomoto, Jeronimo Cello, Eckard Wimmer
    Abstract:

    An important step in poliovirus (PV) infection by the oral route in humans is replication of the virus in lymphatic tissues of the gastrointestinal (GI) tract, thought to be mainly in the Peyer’s patches of the small intestine. No immunocompetent transgenic (tg) mice that express human PV receptor (CD155) under the control of different promoters can be infected orally. The mouse orthologue of human CD155 is Tage4, a protein expressed at the surface of enterocytes and in the Peyer’s patches. We describe here the generation of a tg mouse model in which the Tage4 promoter was used to drive expression of the human PV receptor-coding region (Tage4-CD155tg mice). In this model, CD155 expression was observed by immunostaining in different regions in the Peyer’s patches but not in their germinal centres. Although a similar pattern of staining was observed between 3- and 6-week-old Tage4-CD155tg mice, poliomyelitis was only seen in the younger mice after PV infection by the oral route. When compared with TgPVR21 mice that expressed CD155 driven by its human promoter, 3-week-old Tage4-CD155tg mice were more susceptible to gut infection and paralysis following feeding with PV. Also, Tage4-CD155tg mice exhibited higher susceptibility to poliomyelitis after parenteral inoculation of PV. Remarkably, the LD50 after intracerebral inoculation of PV was similar in both CD155 tg mouse strains. The CD155 tg mouse model reported here, although moderately susceptible to oral infection, may be suitable to study mechanisms of PV replication in the gastrointestinal tract and to dissect important aspects of PV neuroinvasiveness.

  • recruitment of nectin 3 to cell cell junctions through trans heterophilic interaction with CD155 a vitronectin and poliovirus receptor that localizes to αvβ3 integrin containing membrane microdomains
    Journal of Biological Chemistry, 2003
    Co-Authors: Steffen Mueller, Eckard Wimmer
    Abstract:

    Abstract Nectins present a novel class of Ig superfamily adhesion molecules that, cooperatively with cadherins, establish and maintain cell-cell adherens junctions. CD155, the cognate receptor for poliovirus, undergoes cell-matrix contacts by binding to the extracellular matrix protein vitronectin. The significant homology of nectins with CD155 prompted us to investigate the possibility of their interaction. We determined that nectin-3 binds CD155 and its putative mouse homologue Tage4 in cell-based ligand binding assays. Coculture of nectin-3- and CD155-expressing HeLa cells led to CD155-dependent recruitment of nectin-3 to cell-cell contacts. In a heterologous coculture system with CD155 expressing mouse neuroblastoma cells, HeLa cell-expressed nectin-3 was recruited to contact sites with CD155 bearing neurites. CD155 and nectin-3 colocalized to epithelial cell-cell junctions in renal proximal tubules and in the amniotic membrane. Efficient interaction depended on CD155 dimerization, which appears to be aided by cell type-specific cofactors. We furthermore found CD155 to codistribute with αv integrin microdomains on the surface of transfected mouse fibroblasts and at amniotic epithelial cell junctions. Our findings demonstrate the possible trans-interaction between the bona fide cell-cell adherens type adhesion system (cadherin/nectin) and the cell-matrix adhesion system (integrin/CD155) by virtue of their nectin-3 and CD155 components, respectively.

  • complexes of poliovirus serotypes with their common cellular receptor CD155
    Journal of Virology, 2003
    Co-Authors: Steffen Mueller, Eckard Wimmer, Paul R Chipman, Carol M Bator, Xiaozhong Peng, Valorie D Bowman, Suchetana Mukhopadhyay, Richard J Kuhn, Michael G Rossmann
    Abstract:

    Structures of all three poliovirus (PV) serotypes (PV1, PV2, and PV3) complexed with their cellular receptor, PV receptor (PVR or CD155), were determined by cryoelectron microscopy. Both glycosylated and fully deglycosylated CD155 exhibited similar binding sites and orientations in the viral canyon for all three PV serotypes, showing that all three serotypes use a common mechanism for cell entry. Difference maps between the glycosylated and deglycosylated CD155 complexes determined the sites of the carbohydrate moieties that, in turn, helped to verify the position of the receptor relative to the viral surface. The proximity of the CD155 carbohydrate site at Asn105 to the viral surface in the receptor-virus complex suggests that it might interfere with receptor docking, an observation consistent with the properties of mutant CD155. The footprints of CD155 on PV surfaces indicate that the south rim of the canyon dominates the virus-receptor interactions and may correspond to the initial CD155 binding state of the receptor-mediated viral uncoating. In contrast, the interaction of CD155 with the north rim of the canyon, especially the region immediately outside the viral hydrophobic pocket that normally binds a cellular “pocket factor,” may be critical for the release of the pocket factor, decreasing the virus stability and hence initiating uncoating. The large area of the CD155 footprint on the PV surface, in comparison with other picornavirus-receptor interactions, could be a potential limitation on the viability of PV escape mutants from antibody neutralization. Many of these are likely to have lost their ability to bind CD155, resulting in there being only three PV serotypes.

  • immunofluorescence analysis of poliovirus receptor expression in peyer s patches of humans primates and CD155 transgenic mice implications for poliovirus infection
    The Journal of Infectious Diseases, 2002
    Co-Authors: Akiko Iwasaki, Steffen Mueller, Reinhold Welker, Melissa M Linehan, Akio Nomoto, Eckard Wimmer
    Abstract:

    Oral transmission of poliovirus is restricted to humans and certain primate species. The expression of the human poliovirus receptor (CD155) within gastrointestinal-associated lymphoid tissues from species that are susceptible (human) or resistant (rhesus macaque and CD155 transgenic [Tg] mice) to oral poliovirus infection was examined. Sensitivity to oral infection correlated with CD155 expression not only in the intestinal epithelium, including the follicle-associated epithelium (FAE) and microfold (M) cells of Peyer's patches, but also in germinal centers within the Peyer's patches. CD155 expression in rhesus macaques was reduced in FAE and, significantly, absent in germinal centers. In CD155 Tg mice, CD155 expression was barely observable in the intestinal epithelium, absent in germinal centers, but prominent in the tunica muscularis. This suggests that productive poliovirus infection of the gut is dependent on the expression of CD155 within the FAE, including the M cells, and on cells within Peyer's patches, most likely within germinal centers.

  • expression of the human poliovirus receptor CD155 gene is activated by sonic hedgehog
    Journal of Biological Chemistry, 2002
    Co-Authors: David J Solecki, Gunter Bernhardt, Steffen Mueller, Matthias Gromeier, Eckard Wimmer
    Abstract:

    Abstract The human poliovirus receptor/CD155 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. The ectodomain of CD155 mediates cell attachment to the extracellular matrix molecule vitronectin, while its intracellular domain interacts with the dynein light chain Tctex-1. CD155 is a primate-restricted gene that is expressed during development in mesenchymal tissues and ventrally derived structures within the CNS. Its function in adults is as yet unknown, but significantly, CD155 is aberrantly expressed in neuroectodermal tumors. We show that the expression of CD155 mRNA is up-regulated when human Ntera2 cells are treated with purified Sonic hedgehog (Shh) protein. Reporter gene expression driven by theCD155 core promoter is activated by Shh in transient co-transfection assays. Analysis of the CD155 core promoter indicates that an intact GLI binding site is required for Shh activation. In addition, overexpression of Gli1 orGli3 potently activates reporter gene expression driven by the CD155 core promoter. These data identify theCD155 gene as a transcriptional target of Shh, a finding that has significance for the normal function of CD155 during development and the expression of CD155 in neuroectodermal tumors.

Akira Shibuya - One of the best experts on this subject based on the ideXlab platform.

  • tumor derived soluble CD155 inhibits dnam 1 mediated antitumor activity of natural killer cells
    Journal of Experimental Medicine, 2020
    Co-Authors: Genki Okumura, Akiko Iguchimanaka, Rikito Murata, Yumi Yamashitakanemaru, Akira Shibuya, Kazuko Shibuya
    Abstract:

    CD155 is a ligand for DNAM-1, TIGIT, and CD96 and is involved in tumor immune responses. Unlike mouse cells, human cells express both membranous CD155 and soluble CD155 (sCD155) encoded by splicing isoforms of CD155. However, the role of sCD155 in tumor immunity remains unclear. Here, we show that, after intravenous injection with sCD155-producing B16/BL6 melanoma, the numbers of tumor colonies in wild-type (WT), TIGIT knock-out (KO), or CD96 KO mice, but not DNAM-1 KO mice, were greater than after injection with parental B16/BL6 melanoma. NK cell depletion canceled the difference in the numbers of tumor colonies in WT mice. In vitro assays showed that sCD155 interfered with DNAM-1-mediated NK cell degranulation. In addition, DNAM-1 had greater affinity than TIGIT and CD96 for sCD155, suggesting that sCD155 bound preferentially to DNAM-1. Together, these results demonstrate that sCD155 inhibits DNAM-1-mediated cytotoxic activity of NK cells, thus promoting the lung colonization of B16/BL6 melanoma.

  • High expression of soluble CD155 in estrogen receptor-negative breast cancer
    Breast Cancer, 2019
    Co-Authors: Akiko Iguchi-manaka, Genki Okumura, Akira Shibuya, Emika Ichioka, Hiroko Kiyomatsu, Tatsuhiko Ikeda, Hiroko Bando, Kazuko Shibuya
    Abstract:

    Background The poliovirus receptor (CD155) is expressed ubiquitously at low levels on both hematopoietic and nonhematopoietic cells, but its expression is upregulated in various tumor cells. An activating receptor DNAM-1 expressed on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells binds to CD155 and mediates the cytotoxic activity of CTLs and NK cells against tumors. Unlike mouse tissues, human tissues express a soluble form of CD155 (sCD155), which is a splicing isoform of CD155 lacking the transmembrane region. We previously reported that the serum levels of sCD155 were higher in lung, gastrointestinal, breast, and gynecologic cancer patients than in healthy donors. Here, we focus on breast cancer patients. Methods To analyze the association between serum level of sCD155 and clinicopathological parameters of breast cancer, we quantified sCD155 in the sera of 153 breast cancer patients by sandwich ELISA. Results sCD155 levels in the sera of breast cancer patients were positively correlated with patient age, disease stage, and invasive tumor size. Moreover, they were higher in patients with estrogen receptor (ER)-negative cancers than in those with ER-positive tumors, and higher in those with Ki-67-high cancers than in those with Ki-67-low cancers. Conclusions The serum level of sCD155 is correlated with high risk factors in breast cancer.

  • High expression of soluble CD155 in estrogen receptor-negative breast cancer
    Breast Cancer, 2019
    Co-Authors: Akiko Iguchi-manaka, Genki Okumura, Akira Shibuya, Emika Ichioka, Hiroko Kiyomatsu, Tatsuhiko Ikeda, Hiroko Bando, Kazuko Shibuya
    Abstract:

    Background The poliovirus receptor (CD155) is expressed ubiquitously at low levels on both hematopoietic and nonhematopoietic cells, but its expression is upregulated in various tumor cells. An activating receptor DNAM-1 expressed on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells binds to CD155 and mediates the cytotoxic activity of CTLs and NK cells against tumors. Unlike mouse tissues, human tissues express a soluble form of CD155 (sCD155), which is a splicing isoform of CD155 lacking the transmembrane region. We previously reported that the serum levels of sCD155 were higher in lung, gastrointestinal, breast, and gynecologic cancer patients than in healthy donors. Here, we focus on breast cancer patients. Methods To analyze the association between serum level of sCD155 and clinicopathological parameters of breast cancer, we quantified sCD155 in the sera of 153 breast cancer patients by sandwich ELISA. Results sCD155 levels in the sera of breast cancer patients were positively correlated with patient age, disease stage, and invasive tumor size. Moreover, they were higher in patients with estrogen receptor (ER)-negative cancers than in those with ER-positive tumors, and higher in those with Ki-67-high cancers than in those with Ki-67-low cancers. Conclusions The serum level of sCD155 is correlated with high risk factors in breast cancer.

  • increased soluble CD155 in the serum of cancer patients
    PLOS ONE, 2016
    Co-Authors: Akiko Iguchimanaka, Genki Okumura, Hiroko Bando, Hiroshi Kojima, Yukiko Cho, Rei Hirochika, Toyomi Sato, Hiroyuki Yoshikawa, Hisato Hara, Akira Shibuya
    Abstract:

    Emerging evidence suggests that DNAM-1 (CD226) play an important role in the recognition of tumor cells and their lysis by cytotoxic T lymphocytes (CTL) and NK cells. Although the DNAM-1 ligand CD155 is ubiquitously expressed in various tissues, many human tumors significantly upregulate the expression of CD155; DNAM-1 on CTL and NK cells may be involved in tumor immunity. However, unlike those in mice, human tissues also express soluble isoforms of CD155 (sCD155) that lack the transmembrane region. Here, we show that sCD155 levels were significantly higher in the sera of 262 patients with lung, gastrointestinal, breast, and gynecologic cancers than in sera from healthy donors. In addition, the sCD155 levels were significantly higher in patients with early stage (stages 1 and 2) gastric cancer than in healthy donors, and were significantly higher in patients with advanced stage (stages 3 and 4) disease than in patients in those with early stage disease and healthy donors. Moreover, the sCD155 levels were significantly decreased after surgical resection of cancers. Thus, sCD155 level in serum may be potentially useful as a biomarker for cancer development and progression.

  • CD155 cd226 interaction impacts on the generation of innate cd8 thymocytes by regulating inkt cell differentiation
    European Journal of Immunology, 2016
    Co-Authors: Hristo Georgiev, Akira Shibuya, Inga Ravens, Reinhold Forster, Gunter Bernhardt
    Abstract:

    The cell surface receptor CD155 influences a variety of immune processes by binding to its ligands CD226, CD96, or TIGIT. Here, we report that the interaction of CD155 with CD226 in the thymus of BALB/c mice has a dual function. It directly influences the dwell time of memory-like CD8(+) T cells, while it is indirectly involved in generating these cells. It was shown earlier that a massive emergence of memory-like CD8 T cells in thymus crucially depends on abundant IL-4, secreted in steady state by iNKT2 (where iNKT is invariant NKT) cells, a subclass of iNKT cells. Here, we show that absence of either CD155 or CD226 in BALB/c mice causes a profound shift in the iNKT subtype composition in thymus, expanding the frequency and numbers of iNKT1 cells at the expense of iNKT2 cells, as well as iNKT17 cells. This shift results in a drop of available IL-4 and creates a scenario similar to that observed in C57BL/6 mice, where iNKT1 cells predominate and iNKT2 cells are much less frequent when compared with BALB/c mice. Yet also in C57BL/6 mice, lack of CD155 or CD226 provokes a further decline in iNKT2 cells, suggesting that the observed effects are not restricted to a particular inbred strain.

Kazuko Shibuya - One of the best experts on this subject based on the ideXlab platform.

  • tumor derived soluble CD155 inhibits dnam 1 mediated antitumor activity of natural killer cells
    Journal of Experimental Medicine, 2020
    Co-Authors: Genki Okumura, Akiko Iguchimanaka, Rikito Murata, Yumi Yamashitakanemaru, Akira Shibuya, Kazuko Shibuya
    Abstract:

    CD155 is a ligand for DNAM-1, TIGIT, and CD96 and is involved in tumor immune responses. Unlike mouse cells, human cells express both membranous CD155 and soluble CD155 (sCD155) encoded by splicing isoforms of CD155. However, the role of sCD155 in tumor immunity remains unclear. Here, we show that, after intravenous injection with sCD155-producing B16/BL6 melanoma, the numbers of tumor colonies in wild-type (WT), TIGIT knock-out (KO), or CD96 KO mice, but not DNAM-1 KO mice, were greater than after injection with parental B16/BL6 melanoma. NK cell depletion canceled the difference in the numbers of tumor colonies in WT mice. In vitro assays showed that sCD155 interfered with DNAM-1-mediated NK cell degranulation. In addition, DNAM-1 had greater affinity than TIGIT and CD96 for sCD155, suggesting that sCD155 bound preferentially to DNAM-1. Together, these results demonstrate that sCD155 inhibits DNAM-1-mediated cytotoxic activity of NK cells, thus promoting the lung colonization of B16/BL6 melanoma.

  • High expression of soluble CD155 in estrogen receptor-negative breast cancer
    Breast Cancer, 2019
    Co-Authors: Akiko Iguchi-manaka, Genki Okumura, Akira Shibuya, Emika Ichioka, Hiroko Kiyomatsu, Tatsuhiko Ikeda, Hiroko Bando, Kazuko Shibuya
    Abstract:

    Background The poliovirus receptor (CD155) is expressed ubiquitously at low levels on both hematopoietic and nonhematopoietic cells, but its expression is upregulated in various tumor cells. An activating receptor DNAM-1 expressed on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells binds to CD155 and mediates the cytotoxic activity of CTLs and NK cells against tumors. Unlike mouse tissues, human tissues express a soluble form of CD155 (sCD155), which is a splicing isoform of CD155 lacking the transmembrane region. We previously reported that the serum levels of sCD155 were higher in lung, gastrointestinal, breast, and gynecologic cancer patients than in healthy donors. Here, we focus on breast cancer patients. Methods To analyze the association between serum level of sCD155 and clinicopathological parameters of breast cancer, we quantified sCD155 in the sera of 153 breast cancer patients by sandwich ELISA. Results sCD155 levels in the sera of breast cancer patients were positively correlated with patient age, disease stage, and invasive tumor size. Moreover, they were higher in patients with estrogen receptor (ER)-negative cancers than in those with ER-positive tumors, and higher in those with Ki-67-high cancers than in those with Ki-67-low cancers. Conclusions The serum level of sCD155 is correlated with high risk factors in breast cancer.

  • High expression of soluble CD155 in estrogen receptor-negative breast cancer
    Breast Cancer, 2019
    Co-Authors: Akiko Iguchi-manaka, Genki Okumura, Akira Shibuya, Emika Ichioka, Hiroko Kiyomatsu, Tatsuhiko Ikeda, Hiroko Bando, Kazuko Shibuya
    Abstract:

    Background The poliovirus receptor (CD155) is expressed ubiquitously at low levels on both hematopoietic and nonhematopoietic cells, but its expression is upregulated in various tumor cells. An activating receptor DNAM-1 expressed on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells binds to CD155 and mediates the cytotoxic activity of CTLs and NK cells against tumors. Unlike mouse tissues, human tissues express a soluble form of CD155 (sCD155), which is a splicing isoform of CD155 lacking the transmembrane region. We previously reported that the serum levels of sCD155 were higher in lung, gastrointestinal, breast, and gynecologic cancer patients than in healthy donors. Here, we focus on breast cancer patients. Methods To analyze the association between serum level of sCD155 and clinicopathological parameters of breast cancer, we quantified sCD155 in the sera of 153 breast cancer patients by sandwich ELISA. Results sCD155 levels in the sera of breast cancer patients were positively correlated with patient age, disease stage, and invasive tumor size. Moreover, they were higher in patients with estrogen receptor (ER)-negative cancers than in those with ER-positive tumors, and higher in those with Ki-67-high cancers than in those with Ki-67-low cancers. Conclusions The serum level of sCD155 is correlated with high risk factors in breast cancer.

  • CD155 pvr necl5 mediates a costimulatory signal in cd4 t cells and regulates allergic inflammation
    Journal of Immunology, 2015
    Co-Authors: Yumi Yamashitakanemaru, Akira Shibuya, Gunter Bernhardt, Yuichi Takahashi, Yinan Wang, Satoko Taharahanaoka, Shinichiro Honda, Kazuko Shibuya
    Abstract:

    Although Th1 and Th2 cells are known to be involved in allergic inflammatory diseases, the molecular mechanisms underlying their differentiation are incompletely understood. In this study, we identified CD155 as a costimulatory molecule on CD4(+) T cells. Importantly, CD155-mediated signaling induced Th1 development in both humans and mice, as evidenced by production of IFN-γ and upregulation of Tbx21 transcription; these effects were independent of IL-12 but dependent on NF-κB-induced autocrine IFN-γ that triggered positive feedback via STAT1 activation. Mice genetically deficient in CD155 or treated with anti-CD155 Ab exhibited attenuated Th1-type contact hypersensitivity. Thus, CD155 plays an important regulatory role in helper T cell differentiation and allergic diseases.

  • increased cd112 expression in methylcholanthrene induced tumors in CD155 deficient mice
    PLOS ONE, 2014
    Co-Authors: Yoko Nagumo, Akiko Iguchimanaka, Yumi Yamashitakanemaru, Akira Shibuya, Gunter Bernhardt, Fumie Abe, Kazuko Shibuya
    Abstract:

    Tumor recognition by immune effector cells is mediated by antigen receptors and a variety of adhesion and costimulatory molecules. The evidence accumulated since the identification of CD155 and CD112 as ligands for DNAM-1 in humans and mice has suggested that the interactions between DNAM-1 and its ligands play an important role in T cell- and natural killer (NK) cell-mediated recognition and lysis of tumor cells. We have previously demonstrated that methylcholanthrane (MCA) accelerates tumor development in DNAM-1-deficient mice, and the CD155 level on MCA-induced tumors is significantly higher in DNAM-1-deficient mice than in wild-type (WT) mice. By contrast, Cd112 expression on the tumors is similar in WT and DNAM-1-deficient mice, suggesting that CD155 plays a major role as a DNAM-1 ligand in activation of T cells and NK cells for tumor immune surveillance. To address this hypothesis, we examined MCA-induced tumor development in CD155-deficient mice. Unexpectedly, we observed no significant difference in tumor development between WT and CD155-deficient mice. Instead, we found that Cd112 expression was significantly higher in the MCA-induced tumors of CD155-deficient mice than in those of WT mice. We also observed higher expression of DNAM-1 and lower expression of an inhibitory receptor, TIGIT, on CD8+ T cells in CD155-deficient mice. These results suggest that modulation of the expression of receptors and CD112 compensates for CD155 deficiency in immune surveillance against MCA-induced tumors.

Inga Ravens - One of the best experts on this subject based on the ideXlab platform.

  • CD155 cd226 interaction impacts on the generation of innate cd8 thymocytes by regulating inkt cell differentiation
    European Journal of Immunology, 2016
    Co-Authors: Hristo Georgiev, Akira Shibuya, Inga Ravens, Reinhold Forster, Gunter Bernhardt
    Abstract:

    The cell surface receptor CD155 influences a variety of immune processes by binding to its ligands CD226, CD96, or TIGIT. Here, we report that the interaction of CD155 with CD226 in the thymus of BALB/c mice has a dual function. It directly influences the dwell time of memory-like CD8(+) T cells, while it is indirectly involved in generating these cells. It was shown earlier that a massive emergence of memory-like CD8 T cells in thymus crucially depends on abundant IL-4, secreted in steady state by iNKT2 (where iNKT is invariant NKT) cells, a subclass of iNKT cells. Here, we show that absence of either CD155 or CD226 in BALB/c mice causes a profound shift in the iNKT subtype composition in thymus, expanding the frequency and numbers of iNKT1 cells at the expense of iNKT2 cells, as well as iNKT17 cells. This shift results in a drop of available IL-4 and creates a scenario similar to that observed in C57BL/6 mice, where iNKT1 cells predominate and iNKT2 cells are much less frequent when compared with BALB/c mice. Yet also in C57BL/6 mice, lack of CD155 or CD226 provokes a further decline in iNKT2 cells, suggesting that the observed effects are not restricted to a particular inbred strain.

  • cd226 interaction with CD155 impacts on retention and negative selection of cd8 positive thymocytes as well as t cell differentiation to follicular helper cells in peyer s patches
    Immunobiology, 2013
    Co-Authors: Simon Danisch, Akira Shibuya, Kazuko Shibuya, Sebastian Seth, Quan Qiu, Inga Ravens, Reinhold Forster, Martina Dorsch, Gunter Bernhardt
    Abstract:

    The immunoglobulin-like glycoprotein CD226 represents a receptor activating cytotoxic T and NK cells taking part in tumour surveillance. In addition, CD226 is involved in the differentiation of naive CD4(+) T cells into effector cells. CD155 that is widely over-expressed on tumour cells, was identified as a counter-receptor of CD226 rendering many cancer cells sensitive to NK driven elimination. However, CD155 was also assigned a role in the establishment of follicular helper T cells in the small intestine and the final maturation of CD8 positive thymocytes. Here we show that mice lacking CD226 are distinguished by virtually identical phenotypes as already reported for CD155 deficient mice: a paucity of follicular helper T cells in Peyer's Patches and of terminally matured CD8 T cells in thymus. Moreover, like CD155, CD226 is involved in negative selection of CD8 thymocytes. These observations establish a firm link between the functions of CD155 and CD226 in several T cell differentiation steps.

  • absence of CD155 aggravates acute graft versus host disease
    Proceedings of the National Academy of Sciences of the United States of America, 2011
    Co-Authors: Sebastian Seth, Inga Ravens, Reinhold Forster, Gunter Bernhardt, Chunwei Lee, Silke Glage, Andre Bleich, Christian Koenecke
    Abstract:

    In a recent paper, Nabekura et al. (1) provided compelling evidence that abrogating DNAM-1 (DNAX accessory molecule-1; CD226) activity resulted in milder development of graft-versus-host disease (GVHD). This is expected, because the role of CD226 as an important costimulatory receptor during T-cell activation is well-documented (2, 3). As shown in the paper (1), CD226 present on donor T cells contributed to the typical syndromes of GVHD. A milder course of GVHD was also achieved by treating transplanted mice with an antibody neutralizing CD226. The authors assumed that CD226 signaling is initiated by interaction of the allogeneic T cells with host cells expressing either CD112 or CD155, the two known ligands of CD226 (1). We analyzed the development of GVHD in mice deficient for CD155. Unexpectedly, the mice succumbed to GVHD within 1 wk, whereas WT mice survived for approximately 3 wk (Fig. 1A). Additional experiments suggested that the observed aggravation in the course of disease is mainly caused by CD4+ donor T cells (Fig. 1A). Additional analyses aimed at identifying the cause of premature death of CD155−/− recipients failed to reveal any differences to WT controls (Fig. 1B). Serum cytokine levels of IFNγ, IL-6, and TNFα as well as the extent of T-cell proliferation were virtually identical when investigated 3 d posttransplantation. We also subjected the intestine of recipients to a detailed histological examination 6 d posttransplantation, but again, significant differences in the degree of injury or infiltrating T cells between WT and CD155−/− mice were not detected. Of note, CD155−/− mice receiving T cell-depleted bone marrow only developed lethal GVHD after T cells differentiated from donor marrow. This corroborated that CD155−/− mice died of deleterious T-cell effects and not because of constitutional defects imposed by CD155 deficiency (Fig. 1A). Fig. 1 (A) After lethal irradiation, WT BALB/c or CD155−/− (Pvrtm1Gbn) BALB/c (KO) mice received 5 × 106 C57BL/6 T cell-depleted bone marrow cells (BM) alone (n = 8) or BM supplemented with 1 × 106 T cells (CD4+ and CD8+ T cells ... Even if the exact cause of the exacerbated course of GVHD in CD155−/− recipients remains elusive, our results suggest that presence of CD155 may attenuate otherwise devastating consequences of GVHD. Because the study by Nabekura et al. (1) clearly showed that CD226-triggered T-cell coactivation contributes to a worsening course of GVHD, CD155 possibly plays a Janus-faced role in GVHD development: its presence exerts protective effects but at the same time, aggravates GVHD by activating donor cells expressing CD226. Alternatively, as already discussed by Nabekura et al. (1), CD112 expressed by host cells in liver and intestine may be largely responsible for the observed CD226 effects. Future studies involving CD112−/− mice will help to clarify this point. Moreover, the GVHD model in use also matters. Whereas Nabekura et al. (1) chose an experimental strategy eliciting GVHD preferentially by CD8+ T cells, our investigations were based on an MHC fully mismatched model where CD4+ T cells mainly contribute to GVHD development (4). Nevertheless, we were unable to prolong survival time of CD155−/− recipients by treating mice with a CD226 neutralizing antibody (Fig. 1A) (5). Despite its importance in CD4+ T-cell stimulation and differentiation (3), CD226 may, thus, not always play a major role in the complex pathophysiology of GVHD.

  • CD155 is involved in negative selection and is required to retain terminally maturing cd8 t cells in thymus
    Journal of Immunology, 2010
    Co-Authors: Quan Qiu, Sebastian Seth, Michael K Maier, Inga Ravens, Reinhold Forster, Anchana Rathinasamy, Ana Clara Marques Davalosmisslitz, Gunter Bernhardt
    Abstract:

    During their final maturation in the medulla, semimature single-positive (SP) thymocytes downregulate activation markers and subsequently exit into the periphery. Although semimature CD4 + SP cells are sensitive to negative selection, the timing of when negative selection occurs in the CD8 lineage remains elusive. We show that the abundance of terminally matured CD8 + SP cells in adult thymus is modulated by the genetic background. Moreover, in BALB/c mice, the frequency of terminally matured CD8 + SP cells, but not that of CD4 + SP cells present in thymus, varies depending on age. In mice lacking expression of the adhesion receptor CD155, a selective deficiency of mature CD8 + SP thymocytes was observed, emerging first in adolescent animals at the age when these cells start to accumulate in wild-type thymus. Evidence is provided that the mature cells emigrate prematurely when CD155 is absent, cutting short their retention time in the medulla. Moreover, in nonmanipulated wild-type mice, semimature CD8 + SP thymocytes are subjected to negative selection, as reflected by the diverging TCR repertoires present on semimature and mature CD8 + T cells. In CD155-deficient animals, a shift was found in the TCR repertoire displayed by the pool of CD8 + SP cells, demonstrating that CD155 is involved in negative selection.

  • abundance of follicular helper t cells in peyer s patches is modulated by CD155
    European Journal of Immunology, 2009
    Co-Authors: Sebastian Seth, Michael K Maier, Inga Ravens, Elisabeth Kremmer, Reinhold Forster, Usriansyah Hadis, Svenja Hardtke, Gunter Bernhardt
    Abstract:

    The secondary humoral immune response is characterized by plasma B cells secreting isotype-switched and affinity-matured antibodies. The efficient generation of plasma B cells in the GC depends on the presence of follicular helper T (T(FH)) cells, a cell type thought to arise from naive CD4-positive T cells by a hitherto unresolved differentiation pathway. Mice deficient for CD155, an adhesion receptor of the immunoglobulin superfamily, are impaired to mount a secondary humoral immune response upon oral administration of antigen, while the primary IgM response is unaffected. Here, we show that mice lacking CD155 harbor significantly reduced numbers of T(FH) cells in their Peyer's patches. This was paralleled by a decreased frequency of T(FH) cells in the GC. Moreover, the CD155 ligand CD226, which is involved in T-cell activation, is down-regulated during T(FH) cell differentiation, resulting in a complete absence of CD226 on those T(FH) cells residing in the GC. Concurrently, the expression of TIGIT/WUCAM, a newly discovered CD155 ligand, is induced in T(FH) cells. Thus, these cells replace an activating by a putative inhibitory CD155-binding partner during their differentiation.